ABSTRACT The development of antibiotic-resistant bacteria has led to a need for alternatives to antibiotics for growth promotion and disease prevention in poultry production. The helical polysaccharide β-1,3/1,6-glucan is derived from the cell wall of Saccharomyces cervisiae and has immunomodulating activities. The objective of this study was to determine the ability of 2 supplementation programs with a commercial β-1,3/1,6-glucan product to protect broiler chicks from experimental respiratory challenge with Escherichia coli. Chicks were housed in battery-brooders from 1 d of age and fed a standard starter diet or the same diet containing 20 g/ton (22 ppm) of purified β-1,3/1,6-glucan either continuously (BG25d) or for only the first 7 d prior to challenge (BG7d). At d 7 one-half of the birds were inoculated in the thoracic air sac with 800 cfu of a serotype O2, nonmotile strain of E. coli. All surviving birds were necropsied at d 25. Body
INTRODUCTION
The development of antibiotic resistance by pathogenic bacteria has led to a worldwide consideration of limiting the usage of antibiotics in animal agriculture. Recent international legislation and domestic consumer pressures have led to the withdrawal of growth-promoting antibiotics from general usage for a number of poultry companies and have limited those antibiotics available for treating bacterial respiratory infections. It is therefore essential to develop alternative ways of dealing with bacterial challenges in commercial poultry production.
There are a number of potential immunomodulators that may serve as alternatives to antibiotics for both growth promotion and disease resistance in poultry production. The β-glucans are polymers of glucose that can be derived from the cell walls of yeast, bacteria, fungi, 613 weight of survivors and feed conversion efficiency were protected from the adverse effects of E. coli challenge by BG7d but not by BG25d. Mortality was nominally decreased from 63% (control) to 53% in BG25d and 47% in BG7d, but these decreases were not significant. The relative weights of the liver and heart were increased, and the bursa of Fabricius relative weights were decreased by E. coli challenge, and these effects were modulated by β-glucan treatment. Despite positive effects of BG7d in E. coli-challenged birds, the BW of nonchallenged birds was decreased by BG7d and BG25d. These results suggest that supplementation of broiler diets with β-1,3/1,6-glucan may be valuable for decreasing production losses due to E. coli respiratory disease, but that the immune stimulation provided may also result in decreased production values under experimental battery conditions or for birds raised in an environment with minimal disease challenges.
and cereals such as oats, barley, and rye. Each type of β-glucan has a unique structure in which glucose molecules are linked together in different ways, giving them different physical properties. Variations in molecular weight, degree of branching, conformation, and intermolecular associations can affect their biological activity (Bohn and BeMiller, 1995) . There is extensive literature describing the immunomodulating effects of β-glucan in mammals; most of the literature reports an increase in functional activity of macrophages and neutrophils (Reynolds et al., 1980; Cleary et al., 1999; Tzianabos, 2000; Yun et al., 2003) . Discovery of the β-glucan receptor dectin 1 has suggested a commonality between differently branched β-glucan polymers and the involvement of the NF-κB transcription factor (Young et al., 2001) , which can both increase and decrease the inflammatory responses in the mechanisms of β-glucan immunomodulation (Plat and Mensink, 2005) .
One of these molecules, the β-1,3/1,6-glucan from the cell wall of Saccharomyces cerevisiae, is recognized as foreign by the immune systems of mammals, fish, and birds and has been shown to be protective in a number of disease challenge studies (Mansell et al., 1978; Williams and Di Luzio, 1979; Reynolds et al., 1980) . The β-glucans have been shown to improve immune function by activating macrophages, and taken orally, they have been shown to indirectly stimulate innate immunity in the respiratory system of mice by activating macrophages in the Peyer's patches of the gut (Sakurai et al., 1992) . A purified β-glucan from the same manufacturer as that reported here has also been shown to decrease Salmonella enterica serovar Enteritidis organ invasion and stimulate phagocytosis, bactericidal killing, and oxidative burst in heterophils isolated from 4-d-old male Leghorn chickens 24 h after oral challenge (Lowry et al., 2005) . The β-glucans are generally recognized as safe by the Food and Drug Administration for use as food and feed additives. They are widely marketed as immunomodulators in the human nutraceutical market and are sold to improve the survivability of cultured shrimp (Song et al., 1997; Vetvicka, 2001) . Turkey field studies (Bahl and Sorgente, 2002 ) and a controlled turkey battery study (Huff et al., 2002) have suggested that β-1,3/1,6-glucan may be useful as an alternative to growth-promoting antibiotics in poultry production.
The objective of this study was to determine the effect of 2 β-glucan (Immustim) dietary supplementation programs (feeding continuously and feeding for only 7 d prior to infectious challenge) on disease resistance of broiler chicks challenged in an experimental Escherichia coli respiratory infection model.
MATERIALS AND METHODS
Day-old mixed-sex Cobb × Cobb broiler chicks were placed at 10 birds/pen in battery-brooders. There were 3 feed treatments, 2 challenge treatments, and 3 randomly placed replicate pens per treatment. Birds were provided ad libitum access to water and an unmedicated standard corn and soybean ration meeting or exceeding the NRCrecommended allowances (National Research Council, 1994) , and they were kept under incandescent lighting on a light schedule consisting of 23 h light and 1 h dark. A purified β-1,3/1,6-glucan feed supplement (Immustim) was obtained from A. Bahl (Immudyne, Houston, TX) and was added at 20 g/ton (22 ppm or 0.0022%) to the same control broiler starter diet fed to controls. Immustim-supplemented feed was provided either continuously (BG25d) or for only the first 7 d of the experiment (BG7d), after which it was replaced with control feed. Individual birds were weighed, and feed consumption was determined weekly. At 1 wk of age, one-half of the birds given each feed treatment were challenged by inoculating the left cranial-thoracic air-sac with tryptose phosphate broth (Remel, Lenexa, KS) containing approximately 800 cfu of a nonmotile strain of E. coli serotype O2, which had originally been isolated from chickens with colisepticemia. The inoculum was prepared by adding 2 loopfuls of an 18-h culture, which was grown on Columbia sheep blood agar (Remel) at 37°C to 100 mL of tryptose phosphate broth and incubating for 2.5 h in a 37°C shaking water bath. The culture was serially diluted and held overnight for 18 to 20 h at 4°C, and a standard plate count of the challenge dilution was made and counted. Mortality was collected twice each day after challenge, and birds were weighed and examined for lesions of airsacculitis. At 18 d postchallenge all surviving birds were euthanized, weighed, and necropsied. The following key, modified from that described by Piercy and West (1976) , was used to score lesions of airsacculitis/pericarditis observed in both mortalities and at necropsy: 0 = no inflammation; 1 = opacity and thickening of the inoculated air sac; 2 = mild airsacculitis and mild pericarditis; 3 = moderate airsacculitis/pericarditis with spread to liver or abdominal cavity or both (perihepatitis/peritonitis); 4 = severe fibrinous airsacculitis and severe pericarditis; 5 = severe airsacculitis/pericarditis with spread to liver or abdominal cavity or both. Liver, heart, spleen, and bursa were excised and weighed. All livers and air sacs were swabbed with sterile transport swabs (BactiSwabs, Remel) and cultured for 18 to 25 h at 37°C on MacConkey agar (Remel). Representative lactose-negative colonies on MacConkey agar were identified using API 20-E test kits according to the manufacturer's instructions (Bio-Mérieux Vitek Inc, Hazelwood, MO) and were compared with the challenge strain. Recovered isolates were further characterized and compared with the challenge strain using the BioLog Microbial ID system (Biolog, Inc. Hayward, CA).
Statistics
Data were analyzed as a 3 × 2 factorial arrangement using the GLM procedure of SAS software for ANOVA, and means were separated using Duncan's multiple range test and least square means (SAS Inst. Inc., 1988) with pen as the experimental unit. Organ weights were expressed as a percentage of BW and were subjected to arc sine transformation for analysis. A P-value of <0.05 was considered significant unless otherwise stated.
RESULTS
The E. coli challenge significantly reduced BW of surviving birds provided with control feed relative to those control-fed birds that were not challenged (P < 0.0001) and also of birds given continual β-glucan supplementation relative to continually supplemented birds that were not challenged (P = 0.0007). However, E. coli challenge did not decrease BW of birds receiving β-glucan for 7 d relative to unchallenged birds fed β-glucan for 7 d (P = 0.18). The BW of challenged birds fed the 7-d β-glucan treatment were higher than those challenged birds fed the control diet (P = 0.01; Figure 1 ). Body weight of nonchallenged birds was decreased by both the 7-d β-glucan treatment (P =0.03) and the 25-d β-glucan treatment (P = 0.04; Figure  1 ). The feed:gain ratio was improved in E. coli-challenged birds that received the 7-d β-glucan feed treatment (P = 0.002) compared with the nonsupplemented, challenged birds, and there was no effect of β-glucan treatment on feed:gain ratio of nonchallenged controls (Figure 2 ). There were significant interactions between β-glucan and E. coli Differences among control birds (P < 0.05).
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Differences among E. coli-challenged birds (P = 0.01).
affecting both BW (P = 0.004) and the feed:gain ratio (P = 0.02).
Mortality was not significantly affected by treatment but was numerically lower in E. coli-challenged birds fed β-glucan for 7 d (47%, P = 0.09) or 25 d (53%, P = 0.3) compared with nontreated birds (63%; Figure 3 ). Airsacculitis scores were also numerically lower (3.0 vs. 2.3) in birds receiving the 7-d treatment (P = 0.07, data not shown). The relative weights of the liver (Figure 4 ) and heart ( Figure 5 ) were increased in E. coli-challenged birds not supplemented with β-glucan (P = 0.0009) as compared with those in challenged birds provided the 7-d β-glucan treatment. Heart weight was also protected by the 25-d β-glucan treatment ( Figure 5 ). The relative weight of the bursa of Fabricius was not affected by β-glucan supplementation within either the unchallenged or the challenged treatments relative to control fed birds. However, although the relative weight of the bursa of Fabricius was decreased due to E. coli challenge in control-fed or 25-d β-glucan-supplemented challenged birds relative to their respective unchallenged control, the bursa weight of challenged birds given the 7-d β-glucan treatment was not different from the 7-d β-glucan unchallenged control (Figure 6 ). There were significant interactions between β-glucan and E. coli for liver (P = 0.02) and heart (P = 0.006) relative weights. There were no significant differences in Differences between control-fed and both 7-and 25-d treatment among E. coli-challenged birds (P = 0.0001).
the isolation rate of E. coli from the airsacs and livers of challenged birds given different treatments (data not shown).
DISCUSSION
In this study, supplementation of broiler chicken diets with 20 g/ton of a purified β-glucan product for 7 d prior to challenge did not significantly reduce the high level of mortality resulting from a direct air sac injection with E. coli, but it did improve BW and feed conversion efficiency compared with control-fed, challenged birds and decreased pathological changes in organ weights of survivors. Although 7 d of supplementation had some benefit, continuous supplementation for the total 25 d of the study was not beneficial. Although the BW of chicks fed β-glucan for 7 d was not decreased by E. coli challenge, the BW of the control birds that were not challenged with E. coli and were provided β-glucan for either 7 or 25 d was lowered by the β-glucan treatment. Yeast cell wall products such as this β-1,3/1,6-glucan have been shown to prime and activate the inflammatory response, particularly by increasing the function of phagocytes (Tzianabos, 2000) . These results are consistent with the concept that stimulating the immune response can be costly to production (Klasing et al., 1987; Sheldon and Verhulst, 1996) and can be a waste of energy in a nonchallenging environment. Hiss and Sauerwein (2003) have reported that the continuous supplementation of postweaning pig diets with 0.015 or 0.03% of a β-glucan product resulted in a numerical increase in average daily gain but did not increase haptoglobin blood concentration, lymphocyte proliferation, or vaccination responses of piglets. They suggested that merely increasing hygiene might have more profound effects than did supplementation. Dritz et al. (1995) reported 3 experiments with varying outcomes. In one experiment β-glucan supplementation at 0.025% increased growth parameters in postweaning pigs, whereas in the other 2 experiments, 0.1% supplementation had no effect or actually decreased growth rates. These 2 studies exemplify the problems of most antibiotic alternative studies: the results of supplementation are often erratic and variable, unlike the generally more predictable effects of antibiotics. This variability may result from trying to indirectly affect bacterial levels by modulating the complex innate immune system rather than having a direct effect on bacterial killing. Such upregulation of the innate immune system may be beneficial when birds are under a bacterial challenge but can decrease production values when energy is used for an unneeded immune response rather than for growth. This may be why large field studies utilizing these products under the normal stressors inherent in production (Bahl and Sorgente, 2002) can show more production benefit than experimental battery trials conducted under controlled conditions. The improvement in BW and feed conversion afforded birds treated for 7 d suggests that nonspecific immunomodulation using Immustim β-glucan may be useful in preventing some of the losses that can occur during poultry production due to a low level challenge with E. coli in the field but may not be effective in preventing colibacillosis during a severe challenge. Colibacillosis, a localized or systemic infection with Escherichia coli, is the most frequently reported cause of disease and processing plant condemnations (Barnes et al., 2003) . Although E. coli can affect most organ systems of the bird, it is notably the primary cause of airsacculitis, which has been shown to be associated not only with carcass condemnation, but also with decreased BW, increased fecal contamination and processing errors, and higher levels of Campylobacter carcass contamination (Russell, 2003) , making control of these infections essential for food safety as well as for animal health and production. Both acute and subclinical infection with E. coli results in changes in the relative weight of major organs. The in-flammatory response to E. coli challenge increases the weights of the liver and heart and decreases the weight of the bursa of Fabricius, making these measurements useful in evaluating subclinical disease in birds. Although the high level of mortality due to this challenge infection was not significantly decreased, the physiological changes reflected by changes in organ weights of survivors were modulated by BG7d treatment before challenge.
The primary method of controlling E. coli infections in poultry is through the use of therapeutic antibiotics (Barnes et al., 2003) . Since the 1950s subtherapeutic levels of antibiotics have been used to improve production values, particularly feed conversion efficiency, presumably by modifying gut bacterial ecology (Dibner and Richards, 2005) . However, subtherapeutic antibiotics are also credited with decreasing morbidity and mortality from both clinical and subclinical infections with opportunistic pathogens such as E. coli (Gersema and Helling, 1986) and have allowed the development of increasingly intensive confinement animal production. Roura et al. (1992) found that feeding antibiotics to broiler chicks that were either raised in a dirty environment or challenged with Salmonella typhimurium lipopolysaccharide prevented a concurrent decrease in both weight gain and feed efficiency, presumably by preventing immunological stress and its associated metabolic changes. They hypothesized that antibiotics may function by 1) affecting the ability of the immune system to react to challenges, 2) preventing immune activation by decreasing the level of challenge, or 3) a combination of both mechanisms. Dietary supplementation with β-glucan may function in a manner similar to the first mechanism, by modulating innate bactericidal functions and protecting against the losses in production values due to low level, chronic bacterial challenges.
Dietary β-1, 3-glucan has been shown to increase survival of brooder shrimp in both indoor and outdoor tanks (Chang et al., 2000) . Hemocyte phagocytic activity and superoxide anion production was increased, and these effects peaked 24 d after starting the β-glucan supplementation and then decreased to the prefeeding level at the end of a 40-d feeding trial. Although there was significant improvement in disease resistance, the improvement decreased by 9% between d 20 and 40 of the study, leading the authors to suggest feeding β-glucan can lead to immunostimulatory fatigue when fed continuously and should be limited to a 3-wk period or fed intermittently. Our results support this concept; continual supplementation of broiler chicken diets was not as effective as supplementation for 1 wk prior to challenge.
Regulatory and societal pressures to restrict antibiotic use in livestock and recent international marketing agreements that prohibit treating poultry with antibiotics are severely limiting the disease-fighting tools that are available to poultry and livestock producers. There is a need to evaluate potential antibiotic alternatives to improve disease resistance in high intensity food animal production. Nutritional approaches to counteract the debilitating effects of stress and infection may provide producers with useful alternatives to antibiotics. Improving the disease resistance of animals grown without antibiotics will not only benefit the animals' health, welfare, and production efficiency but is also a key strategy in the effort to improve the microbiological safety of poultry products.
These studies suggest that thoughtful and limited supplementation of broiler diets with β-glucan may be valuable for decreasing the production losses due to E. coli respiratory infection in field situations, including lowered BW and reduced feed efficiency. However, our results also suggest that immune stimulation with β-glucan may be costly to the producer in decreased production values for birds that are raised in a clean environment with minimal stress or disease challenge. These data also support the concept that supplementation programs designed to stimulate immunity just prior to predictable environmental stressors and disease exposure may be preferable to continuous treatment because losses due to unnecessary immune stimulation might then be avoided.
